RP-HPLC stability-indicating assay method for talinolol and characterization of its degradation products

Journal of Chromatographic Science

Volumn 49, Issue 10, 2011, Pages 786-795

  Sinha, V R ^a   Ghai, Damanjeet ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 81455142171     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chrsci/49.10.786     Document Type: Article

References (21)

1. B. Kommanaboyina and C.T. Rhodes. Trends in stability testing, with emphasis on stability during distribution and storage. Drug Dev. Ind. Pharm. 25: 857-868 (1999). (Pubitemid 29292917)
2. R.B. Taylor and A.S.H. Shivji. A critical appraisal of drug stability testing methods. Pharm. Res. 4: 177-180 (1999).
3. ICH, Stability testing of new drug substances and products, International Conference on Harmonization, IFPMA, Geneva 2003.
4. B.M. Rao, M.K. Srinivasu, G. Sridhar, P.R. Kumar, K.B. Chandrasekhar, and A. Islam. A stability-indicating LC method for zolmitriptan. J. Pharm. Biomed. Anal. 39: 503-509 (2005).
5. J.R. Bhinge, R.V. Kumar, and V.R. Sinha. A simple and sensitive stability- indicating RP-HPLC assay method for the determination of aceclofenac. J. Chromat. Sci. 46: 440-444 (2008). (Pubitemid 351669009)
6. V.R. Sinha, Monika, A. Trehan, M. Kumar, S. Singh, and J.R. Bhinge. Stress Studies on Acyclovir. J. Chromat. Sci. 45: 319-324 (2007). (Pubitemid 47025393)
7. S. Singh and M. Bakshi. Guidance on conduct of stress tests to determine inherent stability of drugs. Pharm. Technol. 24: 1-14 (2000).
8. M. Bakshi and S. Singh. Development of validated stability-indicating assay methods critical review. J. Pharm. Biomed. Anal. 28: 1011-40 (2002). (Pubitemid 34607392)
9. ICH, Stability testing: Photostability testing of new drug substances and products. International Conference on Harmonization, IFPMA, Geneva 1996.
10. M. Tubic, D. Wagner, H. Spahn-Langguth, M.B. Bolger, and P. Langguth. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect. Pharm. Res. 23: 1712-20 (2006). (Pubitemid 44200533)
11. S. Doppenschmitt, H. Spahn-langguth, C.G. Regardh, and P. Langguth. Role of Pglycoprotein-mediated secretion in absorptive drug permeability: an approach using passive membrane permeability and affinity to P-glycoprotein. J. Pharm. Sci. 88: 1067-1072 (1999). (Pubitemid 29480601)
12. M. Ofer, S. Wolffram, A. Koggel, H. Spahn-Langguth, and P. Langguth. Modulation of drug transport by selected flavonoids: Involvement of P-gp and OCT?. Eur. J. Pharm. Sci. 25: 263-271 (2005). (Pubitemid 40725056)
13. R. Oertel, K. Richter, J. Fauler, and W. Kirch. Increasing sample throughput in pharmacological studies by using dual-column liquid chromatography with tandem mass spectrometry. J. Chrom. A 948: 187-192 (2002). (Pubitemid 34188459)
14. W. Weitschies, A. Bernsdorf, T. Giessmann, M. Zschiesche, C. Modess, V. Hartmann, C. Mrazek, D. Wegner, S. Nagel, and W. Siegmund. The talinolol double peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. Pharm. Res. 22: 728-735 (2005). (Pubitemid 40768584)
15. W. Siegmund, K. Ludwig, G. Engel, M. Zschiesche, G. Franke, A. Hoffmann, B. Terhaag, and W. Weitschies. Variability of intestinal expression of p-glycoprotein in healthy volunteers as described by absorption of talinolol from four bioequivalent tablets. J. Pharm. Sci. 92: 604-610 (2002). (Pubitemid 36258975)
16. A. Hanafya, P. Langguthb, and H. Spahn-Langgutha. Pretreatment with potent P-glycoprotein ligands may increase intestinal secretion in rats. Eur. J. Pharm. Sci. 12: 405-415 (2001).
17. A. Bernsdorf, T. Giessmann, C. Modess, D. Wegner, S. Igelbrink, U. Hecker, S. Haenisch, I. Cascorbi, B. Terhaag, and W. Siegmund. Simvastatin does not influence the intestinal Pglycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Br. J. Clin. Pharmacol. 61: 440-450 (2006).
18. British Pharmacopoeia, The Stationery Office, London, UK, 2003.
19. The United States Pharmacopeia 30, The National Formulary 25, United States Pharmacopeial Convention, Inc. 2007, pp. 249-253.
20. L.R. Snyder, J.J. Kirkland, and J.L. GlaJch. Practical HPLC Method Development, 2nd ed., Wiley, New York, USA, 1997, pp. 253-254.
21. ICH, Q1AR2 Stability testing of new drug substances and products, International Conference on Harmonization, IFPMA, Geneva 2000.